AR081659A1 - Procedimiento de obtencion de la forma cristalina ii del febuxostat - Google Patents

Procedimiento de obtencion de la forma cristalina ii del febuxostat

Info

Publication number
AR081659A1
AR081659A1 ARP110102208A ARP110102208A AR081659A1 AR 081659 A1 AR081659 A1 AR 081659A1 AR P110102208 A ARP110102208 A AR P110102208A AR P110102208 A ARP110102208 A AR P110102208A AR 081659 A1 AR081659 A1 AR 081659A1
Authority
AR
Argentina
Prior art keywords
febuxostat
obtaining
temperature
procedure
crystalline form
Prior art date
Application number
ARP110102208A
Other languages
English (en)
Inventor
Ferre Josep Salaet
Olondriz Francisco Marquillas
Original Assignee
Interquim Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Interquim Sa filed Critical Interquim Sa
Publication of AR081659A1 publication Critical patent/AR081659A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Procedimiento de obtención de la forma cristalina II del Febuxostat por cristalización en un disolvente elegido entre acetato de etilo, acetato de metilo o formiato de etilo.Reivindicación 1: Procedimiento de obtención de la forma cristalina II del Febuxostat, caracterizado porque comprende las siguientes etapas: a) disolución del Febuxostat en un disolvente elegido del grupo consistente en acetato de etilo, acetato de metilo y formiato de etilo en una proporción de 10 a 60 ml de disolvente por gramo de soluto, a una temperatura comprendida entre 50ºC y la temperatura de ebullición de la disolución; b) formación de cristales por enfriamiento de la disolución resultante de la etapa a) a una temperatura comprendida entre 20ºC y 45ºC, opcionalmente durante un período comprendido entre 0.5 y 2 horas con agitación; c) enfriamiento de la suspensión resultante de la etapa b) a una temperatura comprendida entre 0ºC y 30ºC durante un período comprendido entre 0.5 y 3 horas; y d) aislamiento de la forma cristalina II del Febuxostat por filtración y secado.
ARP110102208A 2010-07-13 2011-06-24 Procedimiento de obtencion de la forma cristalina ii del febuxostat AR081659A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201031061 2010-07-13

Publications (1)

Publication Number Publication Date
AR081659A1 true AR081659A1 (es) 2012-10-10

Family

ID=44533538

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP110101868A AR081267A1 (es) 2010-07-13 2011-05-31 Procedimiento de obtencion de la forma cristalina a del febuxostat
ARP110102208A AR081659A1 (es) 2010-07-13 2011-06-24 Procedimiento de obtencion de la forma cristalina ii del febuxostat

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP110101868A AR081267A1 (es) 2010-07-13 2011-05-31 Procedimiento de obtencion de la forma cristalina a del febuxostat

Country Status (7)

Country Link
US (1) US20130184466A1 (es)
EP (1) EP2593442A1 (es)
JP (1) JP2013531021A (es)
AR (2) AR081267A1 (es)
TW (1) TW201217346A (es)
UY (1) UY33511A (es)
WO (1) WO2012007487A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012038971A2 (en) 2010-09-24 2012-03-29 Hetero Research Foundation Novel polymorphs of febuxostat
WO2012168948A2 (en) 2011-06-06 2012-12-13 Hetero Research Foundation Process for febuxostat
CN104114545B (zh) * 2011-11-15 2018-06-01 迈兰实验室有限公司 用于制备非布索坦多晶型物的方法
EP2692342A1 (en) 2012-07-30 2014-02-05 Interquim, S.A. Process for the preparation of pharmaceutical compositions comprising febuxostat in the form of tablets
EP3002006A1 (en) 2014-10-01 2016-04-06 Bluepharma - Industria Farmacêutica, S.A. Pharmaceutical composition capable for the incorporation Febuxostat in the crystalline modifications F10, II, G and A
CN110526879B (zh) * 2019-08-28 2022-06-21 迪嘉药业集团有限公司 一种小粒度非布司他的结晶制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU645867B2 (en) * 1990-11-30 1994-01-27 Teijin Pharma Limited 2-arylthiazole derivative and pharmaceutical composition containing the same
CN101139325B (zh) 2006-09-07 2010-05-12 上海医药工业研究院 2-(3-氰基-4-异丁氧基苯基)-4-甲基-5-噻唑甲酸晶型及其制备方法
CN100546985C (zh) * 2007-06-29 2009-10-07 上海华拓医药科技发展股份有限公司 非布他特微晶及其组合物
CN101412700B (zh) 2007-10-19 2011-06-08 上海医药工业研究院 非布司他的晶型及其制备方法

Also Published As

Publication number Publication date
JP2013531021A (ja) 2013-08-01
US20130184466A1 (en) 2013-07-18
WO2012007487A9 (en) 2012-06-21
TW201217346A (en) 2012-05-01
AR081267A1 (es) 2012-07-18
EP2593442A1 (en) 2013-05-22
WO2012007487A1 (en) 2012-01-19
UY33511A (es) 2012-01-31

Similar Documents

Publication Publication Date Title
AR081659A1 (es) Procedimiento de obtencion de la forma cristalina ii del febuxostat
JP2011126894A5 (es)
JP2009298803A5 (es)
DK2453739T3 (da) Fremgangsmåde til fremstilling af en vandig suspension af en organisk pesticidforbindelse
PL394857A1 (pl) Sposób amonotermalnego wytwarzania kryształów ciągnionych azotku galu na dużą skalę
TW201612179A (en) A process for preparing a crystalline organic semiconductor material
WO2013112884A3 (en) Method for purification of silicon
CO6541539A2 (es) Procesos para preparar las formas cristalinas a y b de ilaprazol y proceso para convertir las formas cristalinas
RU2017123112A (ru) Способ производства кристаллов производного диазабициклооктана и стабильного лиофилизированого препарата
RU2017102893A (ru) Способ отделения тритиевой воды от легкой воды
WO2016016766A3 (en) A process for the preparation of isavuconazonium or its salt thereof
MX2016012260A (es) Resolubilizacion de cristales de proteina a bajo ph.
WO2018069941A3 (en) Polymorphic forms of venetoclax
AR089632A1 (es) Procedimiento de preparacion de la sal de l-arginina de perindoprilo
NO20090914L (no) Halvkontinuerlig fremgangsmate for dannelse, separasjon og smelting av store, rene silisiumkrystaller
MX2016011023A (es) Formulas cristalinas de grapiprant.
RU2016142459A (ru) Способ производства молочной кислоты
WO2015084694A3 (en) Method for preparing crystalline insulin
JP2013528577A5 (es)
UY33510A (es) Procedimiento de obtencion de la forma cristalina a del febuxostat
MY182164A (en) Process for producing acetic acid by introducing a lithium compound
IN2013MU03508A (es)
WO2011066127A3 (en) Preparation of x zeolite
ES2634019T3 (es) Forma cristalina de una sal de trietilamina del ácido tiazolilacético sustituido
RU2011143444A (ru) Способ выращивания кристаллов галогенидов серебра и таллия

Legal Events

Date Code Title Description
FB Suspension of granting procedure